Argininosuccinate synthase 1, arginine deprivation therapy and cancer management
Metabolic reprogramming is an emerging hallmark of tumor cells. In order to survive in the nutrient-deprived environment, tumor cells rewire their metabolic phenotype to provide sufficient energy and build biomass to sustain their transformed state and promote malignant behaviors. Amino acids are th...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-07-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.935553/full |
| _version_ | 1818529213847699456 |
|---|---|
| author | Naihui Sun Xing Zhao |
| author_facet | Naihui Sun Xing Zhao |
| author_sort | Naihui Sun |
| collection | DOAJ |
| description | Metabolic reprogramming is an emerging hallmark of tumor cells. In order to survive in the nutrient-deprived environment, tumor cells rewire their metabolic phenotype to provide sufficient energy and build biomass to sustain their transformed state and promote malignant behaviors. Amino acids are the main compositions of protein, which provide key intermediate substrates for the activation of signaling pathways. Considering that cells can synthesize arginine via argininosuccinate synthase 1 (ASS1), arginine is regarded as a non-essential amino acid, making arginine depletion as a promising therapeutic strategy for ASS1-silencing tumors. In this review, we summarize the current knowledge of expression pattern of ASS1 and related signaling pathways in cancer and its potential role as a novel therapeutic target in cancer. Besides, we outline how ASS1 affects metabolic regulation and tumor progression and further discuss the role of ASS1 in arginine deprivation therapy. Finally, we review approaches to target ASS1 for cancer therapies. |
| first_indexed | 2024-12-11T17:04:03Z |
| format | Article |
| id | doaj.art-6ff0a5717f6c4452beb87778ffe75c4f |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-12-11T17:04:03Z |
| publishDate | 2022-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-6ff0a5717f6c4452beb87778ffe75c4f2022-12-22T00:57:45ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122022-07-011310.3389/fphar.2022.935553935553Argininosuccinate synthase 1, arginine deprivation therapy and cancer managementNaihui Sun0Xing Zhao1Department of Anesthesiology, The First Affiliated Hospital of China Medical University, Shenyang, ChinaDepartment of Pediatrics, The First Affiliated Hospital of China Medical University, Shenyang, ChinaMetabolic reprogramming is an emerging hallmark of tumor cells. In order to survive in the nutrient-deprived environment, tumor cells rewire their metabolic phenotype to provide sufficient energy and build biomass to sustain their transformed state and promote malignant behaviors. Amino acids are the main compositions of protein, which provide key intermediate substrates for the activation of signaling pathways. Considering that cells can synthesize arginine via argininosuccinate synthase 1 (ASS1), arginine is regarded as a non-essential amino acid, making arginine depletion as a promising therapeutic strategy for ASS1-silencing tumors. In this review, we summarize the current knowledge of expression pattern of ASS1 and related signaling pathways in cancer and its potential role as a novel therapeutic target in cancer. Besides, we outline how ASS1 affects metabolic regulation and tumor progression and further discuss the role of ASS1 in arginine deprivation therapy. Finally, we review approaches to target ASS1 for cancer therapies.https://www.frontiersin.org/articles/10.3389/fphar.2022.935553/fullmetabolic reprogrammingarginineamino acidresistanceprognosis |
| spellingShingle | Naihui Sun Xing Zhao Argininosuccinate synthase 1, arginine deprivation therapy and cancer management Frontiers in Pharmacology metabolic reprogramming arginine amino acid resistance prognosis |
| title | Argininosuccinate synthase 1, arginine deprivation therapy and cancer management |
| title_full | Argininosuccinate synthase 1, arginine deprivation therapy and cancer management |
| title_fullStr | Argininosuccinate synthase 1, arginine deprivation therapy and cancer management |
| title_full_unstemmed | Argininosuccinate synthase 1, arginine deprivation therapy and cancer management |
| title_short | Argininosuccinate synthase 1, arginine deprivation therapy and cancer management |
| title_sort | argininosuccinate synthase 1 arginine deprivation therapy and cancer management |
| topic | metabolic reprogramming arginine amino acid resistance prognosis |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2022.935553/full |
| work_keys_str_mv | AT naihuisun argininosuccinatesynthase1argininedeprivationtherapyandcancermanagement AT xingzhao argininosuccinatesynthase1argininedeprivationtherapyandcancermanagement |